Barak Investment House Ltd (TLV: BARI)

Market Cap	21.85M
Revenue (ttm)	19.59M
Net Income (ttm)	-13.40M
Shares Out	430.24K
EPS (ttm)	-88.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Open	5,097.00
Previous Close	5,077.00
Day's Range	5,078.00 - 5,097.00
52-Week Range	1.00 - 17,170.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About Barak Investment House

Barak Investment House Ltd provides pharmaceutical solutions for patients and physicians in Israel and internationally. It offers pharma-grade smokeless cannabis products, such as oral tablets, orodispersible tablets, sublingual tablets, oral oils, sublingual drops, solution for inhalation, pastilles, topicals, suppositories, and cannabis extracts in ethanol under the NAXIVA – PANAXOL, NAXIVA-PANAXOL-ONKO, PANAXIR SENSE, PANAXIR, Axiban, Tikva, Ultra Health, and Salus brands. The company was formerly known as Panaxia Labs Israel Ltd and changed...

• Industry: Pharmaceutical Preparations
• Founded: 2005
• Employees: 10
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: BARI

Financial Performance

In 2023, Barak Investment House's revenue was 19.59 million, a decrease of -50.31% compared to the previous year's 39.42 million. Losses were -13.40 million, -69.02% less than in 2022.